Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis

BACKGROUND: After the approval of pazopanib for the treatment of soft tissue sarcoma (STS), pneumothorax was reported as an unexpected adverse event during pazopanib treatment. The incidence and risk factors of pneumothorax during pazopanib treatment for STSs have not been established yet. METHODS:...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Nakano, Kenji, Motoi, Noriko, Tomomatsu, Junichi, Gokita, Tabu, Ae, Keisuke, Tanizawa, Taisuke, Matsumoto, Seiichi, Takahashi, Shunji
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2016
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5035441/
https://ncbi.nlm.nih.gov/pubmed/27663525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2786-z
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires